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Abstract
Driven by genomic somatic variation, tumour tissues are typically heterogeneous, yet unbiased quantitative methods are
rarely used to analyse heterogeneity at the protein level. Motivated by this problem, we developed automated image
segmentation of images of multiple biomarkers in Ewing sarcoma to generate distributions of biomarkers between and
within tumour cells. We further integrate high dimensional data with patient clinical outcomes utilising random survival
forest (RSF) machine learning. Using material from cohorts of genetically diagnosed Ewing sarcoma with EWSR1
chromosomal translocations, confocal images of tissue microarrays were segmented with level sets and watershed
algorithms. Each cell nucleus and cytoplasm were identified in relation to DAPI and CD99, respectively, and protein
biomarkers (e.g. Ki67, pS6, Foxo3a, EGR1, MAPK) localised relative to nuclear and cytoplasmic regions of each cell in order to
generate image feature distributions. The image distribution features were analysed with RSF in relation to known overall
patient survival from three separate cohorts (185 informative cases). Variation in pre-analytical processing resulted in
elimination of a high number of non-informative images that had poor DAPI localisation or biomarker preservation (67
cases, 36%). The distribution of image features for biomarkers in the remaining high quality material (118 cases, 104 features
per case) were analysed by RSF with feature selection, and performance assessed using internal cross-validation, rather than
a separate validation cohort. A prognostic classifier for Ewing sarcoma with low cross-validation error rates (0.36) was
comprised of multiple features, including the Ki67 proliferative marker and a sub-population of cells with low cytoplasmic/
nuclear ratio of CD99. Through elimination of bias, the evaluation of high-dimensionality biomarker distribution within cell
populations of a tumour using random forest analysis in quality controlled tumour material could be achieved. Such an
automated and integrated methodology has potential application in the identification of prognostic classifiers based on
tumour cell heterogeneity.
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Introduction
Tumours arise in somatic tissues and differ by site of origin,
histological appearance and mechanistic hallmarks [1]. Inter-
tumoural heterogeneity (between individuals) at the genomic,
epigenomic and proteomic level, can be quantified by whole
genome massively parallel (deep) sequencing and quantitative
proteomics [2,3]. Single cell sequencing data have recently also
highlighted the significant intra-tumoural heterogeneity (between
cells of a tumour), the fundamental clonal basis to the often rapid
emergence of resistance to therapies [4–9]. Intra-tumoural
heterogeneity is also modified by cellular and micro-environment
context. Such contexts appear critical to tumour behaviour, but
are generally less well understood, despite the evidence suggesting
that tissue dependent niches established by stromal cell popula-
tions may substantially alter signalling responses and behaviours of
tumour cells [4,10]. In the clinical situation, patients are often
stratified into different clinical cohorts. Further sub-classifications
are either based on outcomes (e.g. survival), by genome wide
analysis and the differential response to drugs, adding further
heterogeneity at the clinical level [11,12]. Despite the complex
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genomic heterogeneity between single cells in different regions
within the same tumour, it remains unclear what the prognostic
significance of these observations are without clinically applied and
unbiased approaches to quantify associated biomarkers of cellular
heterogeneity functional in situ [6,13]. Moreover, ‘omics’ tech-
nologies generate large numbers of quantifiable features that
greatly exceed the numbers of subjects in studies. Such high-
dimensional data thus requires novel approaches to bio-informat-
ics analysis. For cancer, one of the major general problems
remains the unbiased integration of the high dimensional
heterogeneity (distribution) data into predictive, prognostic and
personalised tools that may have genuine clinical utility.
At the level of proteomic localisation in tissues, clinically useful
tissue based proteomics is still largely based on localisation of
protein antibody epitopes in formalin fixed material. For example,
biomarker assessments using immunohistochemistry often remain
semi-quantitative (+1, +2, +3), and lack the cellular localisation
afforded by immunofluorescence and confocal imaging [14]. Use
of MALDI based mass spectrometry [15–18], automated quanti-
tative analysis (AQUA) [19] and multiple-ligand epitope cartog-
raphy (MELC) [20,21] offer significant technical advances, but
they remain prone to bias and fail to address the quantification of
heterogeneity at the resolution of each cell. Advances in unbiased
image analysis, both in 2 and 3 dimensions, have facilitated the
segmentation of regions and cells of tumours, and offer significant
benefits in parallel with developments in fluorescent confocal
microscopy. By high content image analysis, it is now possible to
quantify biomarkers and their distribution in tumours, even
though there are fundamental on-going problems with the
interpretation of thresholds or ‘cutpoints’, in addition to the
emerging quality control problems relating to tissue pre-analytical
processing [19,22–25]. Despite some of these technical limitations,
the more basic application of virtual microscopy and image
analysis to diagnostic pathology have lead to more widespread
technology adoption, and so supports the impetus for the further
development of novel computer algorthims, as for example those
utilised in content retrieval [26,27].
Here, we developed an integrated analysis pipeline to address
the quantification of image feature heterogeneity with clinical
prognostic outcome in a rare but genetically diagnosed tumour.
Ewing sarcoma family of tumours (ES) are rare high-grade
tumours of young adults with an incidence of 0.13 per 100,000
[28]. Diagnostic methodology developments have improved ES
diagnoses, such that current standardisation also identifies the 20%
of cases that arise in soft tissue rather than the more frequent
primary site in bone. ES diagnosis is confirmed by an in situ
hybridisation test based on the EWSR1 gene break-apart probes
(EWS-FLI1, t(11;22)) with histological features of small round cells
and anti-CD99 antibody cytoplasmic labelling [29]. In parallel
with improved molecular diagnosis, combined modality treatment
protocols have also been developed. These treatments incorporate
dose intensive chemotherapy, surgery and radiotherapy and result
in a 60–70% 5-year survival. Patient survival in ES correlates well
with a number of clinical features, such as the good prognosis in
small volume localised tumours with good histological response to
primary treatment [29,30]. There are no prognostic tissue
biomarkers currently in use in ES that have been prospectively
validated, even though ES provides an ideal starting point as these
tumours correlate with a characteristic genotype. There is also
remains a lack of biomarker related studies aiming to either stratify
patients for standard treatments in the clinic, or to be incorporated
into new prospective clinical trials or to be applied in experimental
early phase protocols [31–33]. To date, the Ki67 proliferative
biomarker has been shown to be of potential prognostic
significance in some large series of ES patients using semi-
quantitative single antibody immunohistochemistry [34]. More-
over, biomarker assays to potentially select the 5–15% of patients
more likely to respond to novel IGF pathway intervention remain
unavailable, with drug development programmes curtailed as a
result [35,36].
We sought to develop an unbiased tissue image segmentation
algorithm to quantify downstream signaling biomarkers of
receptor tyrosine kinase activation, detected with antibodies to
signaling proteins and fluorescent probes, and imaged with multi-
spectral confocal microscopy. Using this method to validate
antibody probes firstly in ES cell lines, and then in ES tumour
tissue, we obtained quantification of the distribution of biomarkers
within the nucleus and cytoplasm of each cell within tumour
biopsies assembled on a tissue microarray (TMA). We analysed the
high dimensional distribution data in relation to patient overall
survival using machine learning (random survival forest, RSF) and
utilised the internal validation process in RSF to identify a
prognostic classifier.
Methods
Cell culture
Cells were obtained from ATCC or different partner institutes
of EuroBoNeT (Table S1) [37]. All EWSR1 translocation
confirmed Ewing sarcoma (ES) cell lines used in this study were
grown in RPMI 1640 (PAA Laboratories GmbH, Austria)
supplemented with 1% Penicillin-Streptomycin (PAA Laboratories
GmbH, Austria) and 10% Foetal Calf Serum (Biosera, UK). Three
cell lines (STA-ET 2.1, STA-ET10, WE-68) needed to be
cultivated in gelatine-coated culture flasks to allow cells to attach.
For growth factor experiments cell lines were grown on coverslips
(d = 13 mm) in 24-well plates (Costar, USA) with 46104 cells per
well. Poorly attaching cell lines (e.g. STA-ET 2.1, STA-ET10,
WE-68) were seeded on either Matrigel or gelatine coated
coverslips (growth factor reduced, BD Biosciences, UK). After
adaption for 2 days, cells were serum-starved in RPMI 1640
supplemented with 1% Penicillin-Streptomycin for 24 hr and
treated with IGF2 (50 ng ml21, R&D systems) for 1 hr at 37uC.
Finally cells were fixed in 4% (v/v) formaldehyde for 15 min at
room temperature (RT).
Paraffin-embedded cell cores
Four Ewing cell lines (CHP-100, RD-ES, SK-N-MC, A673)
were grown in petri-dishes (d = 14 cm) for 48 hr prior to 24 hr of
serum starvation. After treatment with IGF2 (50 ng ml21) for 1 hr,
cells were trypsinised (TrypLE Express, Life Technologies, UK)
and centrifuged at 1000 rpm for 5 min. Cells were re-suspended in
4% (v/v) formaldehyde in PBS, and fixed for 1 hr at RT. After
centrifugation at 1300 rpm for 2 min, cells were re-suspended in
2% (v/v) molten agarose at 60uC (Hi-Res standard agarose,
Geneflow, UK)/4% (v/v) formaldehyde in PBS, centrifuged at
2000 rpm for 20 sec and kept on ice for 30 min for the agar to set.
The agarose block containing the cell pellet was dehydrated in an
ascending alcohol series and embedded in paraffin. Five micro-
meter slices were cut and transferred to Polysine slides. Slides were
dried over night at 37uC and stored at 4uC until immune-labelling
was performed within 7 days.
Immunofluorescence
Cells on coverslips were washed in TBS for 563 min,
permeabilised and blocked in TBS/0.5% (v/v) Triton X-100/
10% (v/v) goat serum for 1 hr, and incubated with the primary
antibody at 4uC overnight. Monoclonal rabbit antibodies pS6
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(#4857), Foxo3a (#2497; #9467), EGR1 (#4154) and pMAPK
(#4370) were purchased from New England Biolabs (UK). After 3
washing steps, cells were incubated with a secondary goat anti-
rabbit antibody Alexa 594 (Life Technologies, UK) for 2 hr at RT.
Fluorescent Phalloidin Alexa 488 (Life Technologies, UK) was
used in order to detect the actin cytoskeleton. Cells were incubated
with Phalloidin Alexa 488 (1:50) for 2 hr at RT following 363 min
washes in TBS. Nuclei were detected with the DNA stain DAPI
(Sigma, UK) and coverslips were mounted with Prolong Gold
Antifade (Life Technologies, UK). In order to determine the
dilution of antibodies, we first serially diluted the secondary
antibodies until the signals were at background level. We then
titrated the primary antibodies in the same way, so that signal was
detectable above background. More details for the validation of
the antibody probes are in Table S2. Antibodies were further
validated by use of inhibitors in cell lines (e.g. MCF-7). Reduction
in either signal intensity or altered cellular distribution in response
to IGF2 were confirmed by addition of inhibitors with a range of
concentrations (maximal inhibitory concentration); rapamycin
(10nM), LY294002 (10 mM) and U0126 (10 mM), for pS6 (signal
reduction), Foxo3a (nuclear localization) and EGR1 (cytoplasmic
localization), respectively.
Tissue processing and image capture
Ewing sarcoma TMAs were derived from core biopsies obtained
from the Department of Pathology, University of Valencia, the
Institute of Pathology, University of Du¨sseldorf, Medical Faculty,
and the Department of Pathology, Leiden University Medical
Centre in collaboration with the EuroBoNeT biobank (Table S3).
Written informed consent was obtained for all patient samples,
and TMA cores coded with anonymised codes linked to clinical
data that was also anonymised with the same code, with the latter
data transferred with the physical TMA’s as part of the
EuroBoNET biobank. For tissue assembled into TMA from
Valencia that included the Rizzoli Institute in Bologna, Italy, local
consent was obtained for research on anonymised tumour material
as part of the Prothets-503036 and EuroBoNeT-011814 bio-banks
via the ethical committee of the Rizzoli Institute and Institutional
Ethical Committee of Valencia University, respectively. For tissue
assembled into TMA from Du¨sseldorf, informed consent was
obtained for tissue for studies through the EUROPEAN Ewing
Tumour Working Initiative of National Groups, Ewing Tumour
Studies 1999 (EuroEwing99), in conjunction with institutional
ethics committee of the University of Mu¨nster, Germany. For
tissue assembled in the TMA from LUMC, all samples were
handled according to the Dutch code of proper secondary use of
human material as accorded by the Dutch society of pathology
(www.federa.org). The samples were handled in a coded (pseud-
anonymised) fashion according to the procedures as accorded by
the LUMC ethical board. Importation of anonymised tissue was
approved under UK HTA licence and local ethical review to the
Sarcoma component of the Oxford Research Biobank (HTA
12217, Research Ethics Committee Oxford- C, REC 09/H0606/
5). The HTA licence also covered informed consent for both
importation of material and for project consent for biomarker
studies of signalling proteins in sarcoma tissue.
A total of 524 patients were initially identified from three
cohorts. 472 patients had TMA cores, but not all had outcome
data. 314 potential biopsies were analysed with each TMA
containing one (d = 2 mm, cohort a), three (d = 2 mm, cohort b) or
two (d= 1 mm, cohort c) representative cores for each case,
respectively. Of these, 52 cases had no cores listed on the TMAs
obtained, and 77 had missing cores samples on slides (non-
adherent) even though they had been incorporated into the
TMAs. The remaining 185 cases had both visible cores on the
TMA slides and associated outcome data and were therefore
imaged. 5 mm thick TMA sections were dried for 10 min at RT
before processing. After de-waxing and rehydrating, TMAs were
permeabilised with TBS/0.5% (v/v) Tween20 for 30 min at RT,
and washed several times in distilled water. For antigen de-
masking, slides were immersed in citrate buffer (pH 6.0) and
antigen retrieval was performed in a pressure cooker (Biocare
Medical, UK) for 2 min at 125uC followed by 10 min at 85uC.
Non-specific binding was blocked in TBS/Tween20 (0.5%. v/v)
and 10% (v/v) goat serum for 1 hr at RT. Primary antibodies
rabbit anti-Ki67 (1:300, Thermo Scientific, UK), rabbit anti-Egr1
(1:50), rabbit anti-Foxo3a (1:100) and rabbit anti-pMAPK (1:50)
(New England Biolabs, UK) were incubated simultaneously with
mouse anti-CD99 (1:100, Leica, UK) in a humidified chamber at
4uC over night. After washing in TBS, both secondary antibodies
(goat anti-rabbit Alexa 488 and goat anti-mouse Alexa 555, Life
Technologies, UK) were added together for 2 hr at RT. Slides
were washed and blocked with TBS/10% (v/v) rabbit serum for
1 hour before incubation with the primary conjugate pS6 Alexa
647 (1:30, New England Biolabs, UK, #4851) for 2 hr at RT.
Nuclei were labelled with DAPI and slides were mounted with
Prolong Gold Antifade (Life Technologies, UK). Images were
acquired with an Olympus Fluoview FV1000 confocal microscope
and a 60x oil objective (NA: 1.35). Images of 204862048 pixels,
had a horizontal and vertical dimension of 211 mm6211 mm and a
thickness of 1.292 mm. Between 1 and 6 images per patient were
captured depending on the size of the tissue core. Median filtering
and Gaussian smoothing were applied to all images to reduce
image noise. The total processing of samples to final images took
on average 2-3 days per TMA slide.
Image analysis
Segmentation: To segment individual DAPI stained nuclei,
Otsu’s method was used to initialise a level set algorithm [38]. A
hybrid geodesic region-based level set was used to estimate
location and shape of individual nuclei [39]. This estimate was
corrected using a watershed tesselation for cells in tissues in order
to divide clumps of nuclei. For the cytoplasmic segmentation,
thresholding was used to find the outer boundaries of cells. A
Voronoi tesselation was first calculated based on an equidistant
partitioning between neighbouring cells [40]. The cytoplasm of
cells in cores were segmented firstly with a watershed tesselation,
followed by an iterative marker controlled watershed method to
find the inner boundaries based on the intensity gradient of CD99.
This cytoplasmic segmentation algorithm was then applied to
tissue sections. Nucleus and cytoplasm segmentations were
validated by comparing the computed segmentation results with
manual results drawn by 3 human experts. For this purpose,
images from 3 different cell lines (A673, SK-N-MC, RD-ES) on
coverslips and as cell cores were analysed. The results of the
validation are shown as Bland-Altman plots, which compare the
areas of all nuclei found by 3 experts to the areas according to the
segmentation algorithm, and plots of the Hausdoff distance, which
is the size of the worst mismatch between both segmentation
results. OxBioPathv1 integrates the segmentation and analysis
(below) and is written in Matlab. The total time to process
automated segmentation of all images took 24–48 hours using
University of Oxford computing services.
CD99 and Ki67 thresholding: A Ki67 index for each patient
was defined as the proportion of CD99 positive cells that were
Ki67 positive, as defined by thresholding the log2 (nucleus/
cytoplasmic ratio) of each marker. For the RSF analysis CD99
Heterogeneity of Tissue Biomarkers
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Figure 1. Development of a single cell segmentation algorithm for tumour tissues. Confocal images of agar pellets of EWS-FLI1 positive
Ewing sarcoma cell lines were used to optimise image segmentation. a. Multi-channel and single channel images (with segmentation lines) of the
CHP-100 cell line in cores labelled with DAPI, CD99 and EGR1 biomarkers indicating nucleus and cytoplasm localisation, respectively (see high
magnification insert). In b., .500 cells were manually segmented and compared to the image segmentation algorithm (see Fig. S1 in File S1) using
Bland-Altman and Hausdorff distance. Also, example distributions are shown for nuclear DNA content and nuclear and cytoplasmic localisation of
Heterogeneity of Tissue Biomarkers
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positive cells were defined as those with mean cytoplasmic CD99.
mean nuclear CD99.
Principal Component Analysis (PCA): PCA is a dimensionality
reduction tool which allows an initial visualisation of the data to be
created in two or three dimensions, by searching for linear
combinations of features corresponding to the modes of maximum
variation in the data. Z-scores were calculated to transform all
features to a common scale (mean 0, variance 1) before the PCA
calculation.
Patient features: Individual cell features from all images
associated with a patient were summarised by using kernel density
estimation to approximate the probability density function (PDF)
of each feature. The PDF for each feature was evaluated at 100
equally spaced points.
Automated Quality Control: Image features were only calcu-
lated for those images which passed the quality control criteria,
which primarily related to the numbers and proportion of cells in
focus. In order to support future automation of the entire pipeline,
we built an automated classifier using a set of image features
designed for high content screening (HCS) using the DAPI
channel from images also stained for Ki67 (916 images). 230 of
these images were labelled as poor quality and 686 as good quality.
Four HCS QC features were calculated for each image [41]:
1. Inverse coefficient of variation: Mean image intensity/Stan-
dard deviation image intensity
2. Focus score: Variance image intensity/Mean image intensity
3. Image correlation: A measure of the correlation between
neighbouring pixels in an image, calculated from the grey-level
co-occurrence matrix (GLCM) [42]. Image intensities were
quantised into eight levels, and the GLCM was calculated at a
single scale for neighbouring pixels.
4. Power log-log slope (PLLS, across the whole range): The
change in the intensity power spectrum of an image is
described as a function of spatial frequency. The 2-dimensional
FFT of an image was calculated, and log10 (squared magnitude
of FFT) plotted against log10 (spatial frequency), ignoring
orientation. The gradient of this plot was calculated across the
full spatial frequency range.
An additional eight features were obtained by splitting the
power log-log plot into eight spatial frequency ranges, before
calculating the slope for each. This corresponds to the PLLS at
different image scales. These features were used to train two
logistic regression classifiers to distinguish between good and poor
quality images, one using the first four features (x1-x4), and the
other using all twelve features (x1-x12). The performance was
evaluated using leave-one-out cross-validation.
Random Survival Forest: The RSF training process involved
building a set of decision trees from a subset of the original dataset,
using sampling with replacement (bagging). Since each tree was
built from a different subset of samples the remaining out-of-bag
(OOB) samples provided an unbiased estimate of the error rate,
calculated using Harrell’s concordance index [43], so that 0
indicated a perfect prediction whereas 0.5 would be expected by
chance. At each step during the construction of each tree a
random subset of features was tested for predictive capability. This
ensured all trees were different, contributing to the resilience of
RSF to over-fitting.
In common with most machine learning algorithms, the
performance of RSF was improved by using a feature selection
algorithm to discard irrelevant features. We used the variable
hunting algorithm included in the RSF package, which introduced
an additional random partitioning of the data (80% train and 20%
test) before the forest was trained. Features were iteratively
introduced until no significant features remained, after which the
process was repeated multiple times with a different sampling of
the data. Since each iteration was independent of all others the
importance of a feature could be measured by how frequently it
was selected.
In addition the internal RSF error rates were further validated
using cross-validation in which the data set was randomly
partitioned into a training set consisting of two-thirds of the
samples on which the RSF was trained, with the remaining one-
third of samples used for testing. This was repeated 50 times for
each set of features. Cross-validation is a valuable tool for
analysing the expected performance of the algorithm since a single
analysis may lead to an apparently well (or poorly) performing
EGR1. Image segmentation was applied to tissue microarrays of c. Ewing sarcoma core biopsies on a tissue microarray (TMA), and d., multi-channel
confocal images captured for DAPI, CD99 and Ki67 proliferation marker. In e..500 cells from TMA cores were manually segmented and compared to
the image segmentation algorithm using Bland-Altman and Hausdorff distance, with distributions for DNA and Ki67. Bars: 20 mm (a. and d.), and in c,
200, 100 and 50 mm, respectively.
doi:10.1371/journal.pone.0107105.g001
Table 1. Clinical features of patients with informative images from cohorts utilised in combined random forest analyses.
Ewing sarcoma clinical features Cohort a (n=43) Cohort b (n =16) Cohort c (n =59)
Status (% alive) 70 25 54
Male: Female ratio 1.26:1 3:1 1.23:1
Mean age 19 19 18
Site (%, central: peripheral: extra-osseous) 39:33:28* 19:75:6 24:76:0
Tumour volume (%, ,200 ml: $200 ml: ND) 63:25:12 13:25:62 NA
Metastasis (% Yes: No: ND) 98:0:2 69:19:12 34:66
Translocation (%, EWS-FLI1: Non-FLI1#: ND) 77:9:14 31:38:31 88:0:12
*ND cohort a = outside bone
#Non EWS-FLI1 = EWS-ERG; EWS-NFATC2 or EWSR1-re-arranged (no FLI or ERG partner).
Note: all patients treated in Europe with standard chemotherapeutic, radiotherapy and surgical trial protocol (EICESS92/EE99 CESS81).
ND: data not available.
doi:10.1371/journal.pone.0107105.t001
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algorithm by chance, whereas the use of multiple resamplings
mimics the analysis of multiple different datasets.
RSF parameters:
Number of trees: 1000
Splitting rule: Logrank random (default)
Number of features tested at each split: N/3 (default).
Results
Cell line segmentation
We first obtained imaging data of biomarker localisation and
distributions using unbiased image segmentation of cell lines and
cell line cores. A panel of 10 validated ES cell lines (Table S1) were
exposed to serum free culture and to the growth factor ligand,
insulin-like growth factor 2 (IGF2). A novel image segmentation
algorithm (see methods) was used to identify the boundaries of the
nucleus and cytoplasm of each cell (Figure S1 and S2 in File S1).
Simultaneous fluorescent detection of Phalloidin, DAPI and
signaling biomarkers such as pS6, Foxo3a or EGR1, were imaged
by multi-spectral confocal microscopy (Figure S2 in File S1).
Segmented images were validated relative to three experts using
Hausdorff (maximum discrepancy between boundaries) and
Bland-Altman plots of segmented areas (Figure S2b, d, f in File
S1). Cumulative frequency plots revealed cell line specific effects of
biomarker distributions within the nucleus and cytoplasm of each
cell in response to IGF2, indicating there was significant
heterogeneity between each cell’s response within a given cell
culture, and that the biomarker antibodies were informative for
response (Figure S3 in File S1). An improved version of the
segmentation algorithm was then validated using the same cell
lines assembled into cell pellets, where there were frequent
associated clumps and overlapping cells that more closely
resembled tumours (Figure 1a, b and Figure S4 in File S1).
Tissue micro-array segmentation
Image segmentation of Ewing sarcoma tissue biopsy cores from
three separate but similarly treated ES clinical cohorts (Table 1)
assembled TMAs (Figure 1c, d) were next validated using Bland-
Altman and Hausdorff plots (Figure 1e). The accuracies of the
image segmentations in cell culture, cell pellets and tumours were
relatively similar, although overlapping cells and the disrupted cell
architecture in tumours presented more challenges to the final
segmentation algorithm. The number of cells segmented per
image was in the range 50–500 depending on cell density, and up
to 4 images were captured from random sites on each TMA core.
We utilised TMAs where cores were present on slides linked to
clinical outcome data for 185 ES cases confirmed by EWSR1
break apart in situ hybridisation probes sourced from the three
separate patient European cohorts (a = 57, b = 20, c = 108).
Following imaging of all TMA cores labelled with DAPI, CD99
and pS6, we then applied strict image based quality control criteria
in order to discard non-informative images, including those where
nuclei could not be segmented using DAPI (Figure S5 in File S1).
Image normalisation included controlling for image bias of the
confocal microscope, image pre-processing and comparison of
feature values between cohorts. As a result of the quality control
based on these criteria for each image, 36% of the sampled images
had to eliminated because of poor quality (67/185), leaving a total
of 118 cases with truly informative images suitable for further
analysis (Table 1, a = 43, b = 16, c = 59).
The elimination of a significant number of samples as a result of
quality control indicates that sample pre-analytical processing is a
key and independent determinant of the utility of biomarker
analysis. The formalin fixed samples assembled into paraffin
blocks were processed by local laboratories in the different cohorts.
There were no systematic records collected for the processing and
storage of the blocks and only local guidelines stipulated for the
diagnostic samples. The primary core blocks were sampled and
assembled in the TMAs specific for each cohort. We assume that a
large source of variation relates to timing of tissue collection and
fixation, the length, type and conditions of storage of samples as all
such pre-analytical steps contribute to variations in sample quality
and biomarker stability.
The Kaplan Meier overall survival analysis confirmed that the
patient outcome was different between cohorts (Figure S6 in File
S1). These differences were due to different relative proportions of
patients with relatively good or bad prognosis in each cohort.
Importantly, the informative cases that were imaged were however
representative of the total for all cohorts combined (passed and
failed), and with respect to the different survival outcomes per
cohort (Figure S6 in File S1). We tried to confirm our use of
manual criteria to select images that could be informative by
building a logistic regression classifier for quality control of high
content imaging using the passed and failed images. In the two
classifiers tested, we failed to clearly identify the passed and failed
images, with the AUC for ROC curves both being 0.72 (Figure S7
in File S1). Thus the images of the samples that had not passed
quality control could yet be informative in terms of clinical
outcome data, but it remains necessary to develop quality control
classifiers in the future to select regions in tumours that can be
analysed.
Within the informative imaged data, significant differences still
existed within each cohort with respect to principle component
analysis (PCA), in line with the differences in patient survival,
although as expected TMA cores for the same patient imaged
separately segregated together and were found to be relatively
consistent (Figure S8 in File S1). The patient samples within each
cohort appeared heterogeneous in terms of outcome data as
above, reflecting not only the differences in survival in each cohort,
but also suggesting the importance of normalised pre-analytic
processing to reduce data variation [44]. Overall, 476 multi-
spectral registered confocal images were captured from material
from 118 patients and resulted in the segmentation of a total of
113,201 individual cells with an average of four biomarkers per
cell (104 features per patient). Each biomarker was associated with
a cellular distribution (in relation to the nucleus-DAPI and
cytoplasm-CD99 segmentation) in each cell. Although the
remaining 118 imaged cases did not differ in survival from the
combined cohort, the final number of patients would normally
severely limit the potential for a conventional training and
validation approach to the characterisation of single biomarkers
using the separately identified cohorts. In addition, as others have
found, our data undermines the assumption of the REMARK
guidance, that non-normalised data from separate cohorts are
similar enough to make experimentally valid attempts at
conventional cross-validation of imaging biomarkers [45]. More-
over, the high-dimensionality of our data set compared to the size
of the patient cohorts even if we had included all patients, would
have still remained the main challenge to any subsequent analysis.
This would have remained the case even if several hundred high
quality validation samples could have been identified. Table S3
lists the anonymised patient data with respect to imaged data. Raw
images and software can be freely downloaded; http://www.ibme.
ox.ac.uk/research/biomedia/software-and-datasets.
Conventional biomarker analysis
In order to analyse the pooled image distribution feature data,
we first undertook a conventional threshold approach. By
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combining an exhaustive range of thresholds (cut-points) with
respect to the labels Ki67 (the proliferative marker) and CD99 (the
cytoplasmic marker) with overall patient survival, a weighted
regression accounted for non-linear dependence between total
absolute intensity and intensity ratios using informative images
(Figure S2 in File S1). We plotted Cox proportional hazards p
values of the survival functions for each threshold setting on a heat
map (Figure 2a). Using the maximal significance threshold
(annotated in Figure 2a), log rank significance values were then
also plotted for all possible splits (cut-points) of patients into two
groups (Figure 2b). The data for the maximal significance value
was utilised to generate the Kaplan-Meier plot (Figure 2c). By
taking the same set of images, one experienced observer (CB) also
screened the same images independently of the machine derived
cut point and scored them using a visual threshold of whether
samples showed subjectively high or low proportion of Ki67
labelling. The results showed that the Kaplan-Meier plots from the
maximum threshold cut-point determined systematically, and the
subjective decision of the independent observer appeared surpris-
ingly similar, although not identical (Figure 2c and 2d). These data
suggest that there are significant risks of bias when taking a
subjective threshold value based on an observer, but also an
inherent risk of setting incorrect thresholds if applied indiscrim-
inately by a conventional image analysis to all cells in the image,
and setting an arbitrarily determined threshold or cut-point. Both
approaches have bias in that either might obscure or enhance the
predictive role of a biomarker, for instance due to multiple
comparisons leading to a significant result by chance.
Random survival forest analysis
An alternative analysis was undertaken with an unbiased
machine learning tool random survival forest (RSF). RSF was
applied to the combined cohort of image features and associated
overall survival data. Random forests (RF) and variants are
powerful machine learning tools to automatically generate
Figure 2. Image thresholds bias significance of tissue biomarker results. a. Thresholds for CD99 and Ki67 were split into centiles of the log2
(nuclear/cytoplasmic ratio) distribution. The heat map shows the Cox regression p value (log10) for each pair of centiles with respect to survival
outcome of the whole imaged cohort. The square marker shows the optimal threshold with respect to the p value (CD99; 20.18 [62%tile], Ki67; 0.31
[22%tile]. b. Using this pair of thresholds, the Ki67 index and the log-rank test is calculated for all possible dichotomised splits of patient groups. c.
Optimal threshold values defined in a. and b. lead to the Kaplan-Meier plot of overall survival outcome for good (low Ki67 index, blue) and poor
prognosis (high Ki67 index, red) cases (dotted lines; 95% confidence intervals). Cox regression (b = 1.6, z = 4.8, p = 1.661026, log-rank p = 2.661027). d.
A single observer (CB) scored the same images for Ki67 labelling by eye based on a binary low (blue) or high (red) score, resulting in the Kaplan Meier
plot (Cox regression = 1.3, z = 3.7, p = 2.561024, log-rank p= 161024).
doi:10.1371/journal.pone.0107105.g002
Heterogeneity of Tissue Biomarkers
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e107105
T
a
b
le
2
.
Im
ag
e
fe
at
u
re
d
is
tr
ib
u
ti
o
n
s
u
ti
lis
e
d
in
n
in
e
in
d
e
p
e
n
d
e
n
t
ra
n
d
o
m
su
rv
iv
al
fo
re
st
an
al
ys
e
s.
R
a
n
d
o
m
S
u
rv
iv
a
l
F
o
re
st
B
io
-M
a
rk
e
r
d
is
tr
ib
u
ti
o
n
s
N
A
ll
fe
a
tu
re
s
V
a
ri
a
b
le
h
u
n
ti
n
g
V
H
R
a
n
d
-C
V
m
e
an
st
d
e
v
m
e
an
st
d
e
v
1
D
A
P
I1
1
1
8
0
.5
4
0
.4
5
0
.0
9
3
0
.4
9
0
.0
5
5
2
C
D
9
9
-
D
A
P
I2
1
1
8
0
.5
7
0
.5
3
0
.0
8
6
0
.5
4
0
.0
6
4
3
C
D
9
9
+
D
A
P
I3
1
1
8
0
.5
5
0
.4
8
0
.0
8
7
0
.5
0
0
.0
8
3
4
K
i6
7
4
1
1
8
0
.4
3
0
.3
6
0
.0
8
5
0
.3
8
0
.0
6
4
5
C
D
9
9
-
K
i6
7
5
1
1
8
0
.4
0
0
.3
6
0
.0
9
5
0
.3
8
0
.0
7
3
6
C
D
9
9
+
K
i6
7
6
1
1
8
0
.4
3
0
.4
0
0
.0
8
0
0
.4
1
0
.0
6
5
7
C
D
9
9
6
D
A
P
I
K
i6
7
7
,
8
,
9
1
1
8
0
.4
4
0
.3
9
0
.0
9
2
0
.3
9
0
.0
6
2
8
C
D
9
9
6
D
A
P
I
K
i6
7
Eg
r1
Fo
xo
3
a
p
S6
7
,
8
,
9
1
1
4
0
.5
0
0
.3
9
0
.0
8
9
0
.4
0
0
.0
6
2
9
C
D
9
9
6
D
A
P
I
K
i6
7
Eg
r1
Fo
xo
3
a
p
S6
p
M
A
P
K
7
,
8
,
9
5
0
0
.4
2
0
.4
8
0
.1
5
8
0
.4
8
0
.1
0
4
1
D
A
P
I:
N
u
cl
e
ar
D
A
P
I
(t
o
ta
ls
an
d
m
e
an
s)
in
al
l
ce
lls
.
2
C
D
9
9
-D
A
P
I:
N
u
cl
e
ar
D
A
P
I
in
C
D
9
9
-
ce
lls
.
3
C
D
9
9
+D
A
P
I:
N
u
cl
e
ar
D
A
P
I
in
C
D
9
9
+
ce
lls
.
4
K
i6
7
:
K
i6
7
n
u
cl
e
ar
:
cy
to
p
la
sm
ra
ti
o
s
(t
o
ta
ls
an
d
m
e
an
s)
in
al
l
ce
lls
.
5
C
D
9
9
-K
i6
7
:
K
i6
7
in
C
D
9
9
-
ce
lls
.
6
C
D
9
9
+K
i6
7
:
K
i6
7
in
C
D
9
9
+
ce
lls
7
,
8
,
9
C
D
9
9
+
M
u
lt
ip
le
m
ar
ke
rs
in
C
D
9
9
+
an
d
C
D
9
9
-
ce
lls
.
N
:n
u
m
b
e
r
o
f
p
at
ie
n
ts
.S
o
m
e
p
at
ie
n
ts
d
id
n
o
t
h
av
e
a
fu
ll
se
t
o
f
la
b
e
lle
d
im
ag
e
s,
so
th
e
n
u
m
b
e
r
o
f
sa
m
p
le
s
u
se
d
fo
r
e
ac
h
R
SF
va
ri
e
s
d
e
p
e
n
d
in
g
o
n
th
e
co
m
b
in
at
io
n
o
f
m
ar
ke
rs
u
se
d
.O
n
e
p
at
ie
n
t
d
id
n
o
t
h
av
e
an
y
ce
lls
la
b
e
lle
d
w
it
h
K
i6
7
.A
ll
fe
at
u
re
s:
th
e
o
u
t-
o
f-
b
ag
e
rr
o
r
ra
te
ca
lc
u
la
te
d
o
n
a
cl
as
si
fi
e
r
co
n
ta
in
in
g
al
lf
e
at
u
re
s
fr
o
m
th
e
in
d
ic
at
e
d
m
ar
ke
r
d
is
tr
ib
u
ti
o
n
s.
V
ar
ia
b
le
h
u
n
ti
n
g
:t
h
e
in
te
rn
al
te
st
se
t
e
rr
o
r
ra
te
u
si
n
g
a
R
SF
tr
ai
n
e
d
u
si
n
g
va
ri
ab
le
h
u
n
ti
n
g
fe
at
u
re
se
le
ct
io
n
,
an
d
ar
e
th
e
m
e
an
an
d
st
an
d
ar
d
d
e
vi
at
io
n
s
o
f
th
e
e
rr
o
r
ra
te
s
ar
e
sh
o
w
n
.
V
H
R
an
d
-C
V
:
th
e
m
e
an
an
d
th
e
st
an
d
ar
d
d
e
vi
at
io
n
o
f
th
e
cr
o
ss
-v
al
id
at
io
n
e
rr
o
r
ra
te
u
si
n
g
a
R
SF
tr
ai
n
e
d
u
si
n
g
va
ri
ab
le
h
u
n
ti
n
g
fe
at
u
re
se
le
ct
io
n
,
w
it
h
5
0
ro
u
n
d
s
o
f
tw
o
-t
h
ir
d
s
tr
ai
n
:
o
n
e
-t
h
ir
d
te
st
se
ts
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
7
1
0
5
.t
0
0
2
Heterogeneity of Tissue Biomarkers
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e107105
predictions from a dataset by combining multiple features, each of
which may have a highly skewed non-linear distribution [46].
Importantly, RF can take into account both interactions and
dependencies between features without them being explicitly
encoded. Unsupervised analysis can also result in a form of
clustering analysis, and this basic form of RF has been successfully
applied to immuno-histochemistry based classification [47]. RSF is
a specific supervised random forest variant recently developed that
allows integration of multiple independent features to generate a
predictive tool with respect to patient outcome (prognosis) in the
form of time dependent survival data, without requiring the user to
specify thresholds or cut-points [48,49]. Importantly, the use of
randomised ‘leave out’ and random feature selection reduce the
problems of over-fitting inherent in many machine learning
algorithms, particularly in our case with low sample numbers, and
the lack of independent high quality validation patient sets.
Nine RSFs were performed (Table 2) and trained on the patient
distribution features obtained from single cell features using the
iterative variable hunting (VH) feature selection algorithm to
identify features which were predictive of patient outcome, with
overall cross-validation error rate measured using Harrell’s
concordance index (Figure 3) [43]. Instead of calculating a single
error rate, which might be abnormally high or low due to chance,
we obtained a distribution of error rates from the multiple
iterations (Figure 4a), giving a more realistic view of the
performance of the algorithm. Error rates were lower (,4.0) in
the RSF with Ki67, Ki67 combined with DAPI and Ki67
combined with EGR1, Foxo3a and pS6 markers (Table 2,
Figure 4a). Significant features were identified by comparing the
number of times a feature was selected for the final model out of
the 100 random VH iterations. For example, the ‘CD99 negative
Ki67’ RSF selected the feature ‘CD99 negative Ki67 mean
nuclear/cytoplasm ratio’ at the 63rd centile a total of 73 times
(Figure 4b). The distribution of each patient’s features for CD99
negative Ki67 mean nuclear/cytoplasmic ratio are shown (insert
higher magnification, Figure 4c), along with the final five selected
features marked by green dashed lines. Each feature of the
classifier, although normally combined together, is also shown as
single features compared to relative mortality (Figure 4d). Note
that this shows the relative contribution to the RSF prediction of
that feature, and importantly does not necessarily mean that the
single feature could be used as a predictor on its own.
The internally generated RSF error rates should be unbiased,
and to further validate this we used randomised cross-validation
which, as expected, showed error rates consistent with this
(variable hunting cross-validation, Table 2). This also enabled us
to better understand the variation in performance by visualising
the change in predicted output, as summarised by four of the
cross-validation predictions for the CD99 negative (low cytoplas-
mic labelling) Ki67 RSF (Figure 5). Predicted mortality and
survival plots for the test sets from 25 of all 50 partitions ranked by
error rate are also shown (Figure S10, S11 and S12 in File S1).
Ki67 has been proposed as a prognostic biomarker for Ewing
sarcoma, although here we specifically identified a sub-group of
cells that were Ki67 positive but relatively CD99 negative, that is
the nuclear/cytoplasmic ratio of the CD99 marker was less than 1
(Figure S9 in File S1). Following this result, we were able to
specifically identify this population of cells in images that may have
been overlooked using single biomarker analysis (Figure S13 in
File S1). The biological basis of this top ranked feature, and the
potential for an undifferentiated sub-population that it may
represent, remains unknown. For example, the identification of
CD133 positive stem cells would still require further experimental
investigation [50–52]. Although the RSF classifier predicted
mortality, the predictions for survival outcome were also
consistent, and demonstrate the validity of the RSF classifier
method (Figure S10, S11 and S12 in File S1). Importantly, each
patient’s predicted survival could be modelled, leading to a
personalised prediction and risk stratification that fully incorpo-
rates heterogeneity of that patient’s feature distributions.
Figure 3. Random survival forest analysis of biomarker image
feature distributions. An overview of the imaging, the RSF survival
analysis algorithm and validation approach. Single cell features are
combined into patient features by estimating the probability distribu-
tion (PDF) for each feature, and taking measurements of each
distribution at 100 points. Each RSF is used to analyse all patients,
with prognostic features identified. The use of bagging in each RSF
means error rate estimates should be unbiased, and this is verified
using randomised cross-validation. This procedure also allows the
variability in performance of the algorithm to be simulated without
requiring an additional dataset.
doi:10.1371/journal.pone.0107105.g003
Heterogeneity of Tissue Biomarkers
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e107105
Heterogeneity of Tissue Biomarkers
PLOS ONE | www.plosone.org 10 September 2014 | Volume 9 | Issue 9 | e107105
Discussion
We have been motivated to develop an unbiased analysis
pipeline that is directed at the cellular distribution of biomarkers in
tumours because of the biological problem of cell heterogeneity.
Data integration strategies aimed at quantification of the hetero-
geneity of cells within a tumour are relatively under-developed,
and may be limited by current multi-variate approaches.
Automated methods for unbiased quantification of images have
also been applied, yet frequently lack resolution at the individual
cell, making it difficult to infer whether distributions (heterogene-
ity) between cells was evident [53]. Processing of high dimensional
biomarker data has however been improved by application of
machine learning algorithms, such as random forests, and so
provide an important platform whereby informative components
of data have the potential to be incorporated into a multi-
parameter classifier [54].
Whilst the use of image segmentation in tissue sections has been
widely applied, the analysis has largely been restricted to
segmentation methodology, rather than to a complete integration
with subsequent biomarker analysis in a clinically characterised
sample set [55–57]. We validated known methods of image
segmentation following capture of high resolution fluorescent
confocal images from genetically defined tumour cell lines and
tumour tissue [58]. The distributions of simultaneously captured
fluorescent biomarkers within each cell of image were obtained
using cytoplasmic and nuclear masks, and these were used to
define boundaries between each cell. Here image segmentation
was performed using two steps. The first used the well
characterised local initiated thresholds using ‘level sets’ to define
nuclear boundaries, which was then combined with a cytoplasmic
marker iterative watershed method to segment cytoplasmic and
cell boundaries. The distribution of image features within each cell
and between all cells segmented in the image represents tumour
cell heterogeneity. With the number of probes and images, we
quickly generated high dimensional data per patient. Importantly,
we incorporated information on heterogeneity by splitting the
distribution of each biomarker (probability density function) in 100
equal segments (Figure 3). Importantly, by this novel approach, we
captured the distributions of these features, and incorporated all
the data into a random survival forest (RSF) tool to generate a
prognostic classifier. When integrated analysis combining image
analysis with biomarker evaluation has been performed, for
example in the analysis of breast cancer stroma and in a RSF
analysis in renal cell carcinoma, clinically significant findings were
frequently generated when combined with methodology develop-
ment [45,59]. These precedents lead us to apply our unbiased
methodology pipeline that integrated image acquisition, image
segmentation and machine learning with RSF, to the discovery a
clinical prognostic classifier.
In order to maximise the potential of the pipeline we needed to
attempt to minimise variation in a test example. Variation includes
fundamental differences in tumour cells attributed to different
driver mutations, and to the differences in clinical outcome
attributed to non-standardised diagnosis, stage of disease and
treatment modalities. By sourcing cohorts of Ewing sarcoma
biopsy material associated with standardised clinical management
and outcome data, we attempted to enrich for molecular and
clinical homogeneity, such that differences in outcome may be
more likely to be attributed to differences in tumour behaviour
sampled by the biomarkers that we quantified. Our initial
observations indicated that there was considerable biomarker
variation between different patients, but this was mainly in the
quality of tissue material available for analysis, such that the
potential of what initially appeared a unique combined cohort was
significantly limited to samples that could actually be reliably
analysed by the pipeline (informative material). This was an
important observation and similar to those reported by others,
especially in TMA assembled formalin fixed material [25,60,61].
Moreover, such observations undermine any analysis of separately
collected and stored tissues under variable pre-analytic processing
conditions, as combining these data sets are likely to compound
either biased high content or even standard histological scoring
systems using immuno-histochemistry. For future prospective
validation, improved tissue ischaemic time and optimal preserva-
tion, such as with combined paraffin coating and nitrogen storage,
will likely be mandatory [44,62,63].
Despite the limitation with material quality, the informative and
high quality material lead to the identification of biomarker
heterogeneity between each cell of a Ewing tumour core biopsy,
including in the commonly assayed signalling pathways frequently
deranged in these tumours, namely the MAPK and IGF-PI3K
pathways. Our unbiased pipeline with RSF verified Ki67 as a
potentially informative prognostic biomarker in terms of patient
survival, but only it appears in a subset of cells with lower CD99
labelling than in the total cell population. It is known that cellular
hierarchies exist in tumours, exemplified by rapid proliferative cell
types (Ki67 positive), and concept of the cancer stem cell or
tumour progenitor cells, that initiate and sustain tumour growth.
For example, CD133 positive ES cells have been isolated that can
sustain tumour growth through serial transplantation, and can
differentiate into other lineages such as adipocytes and osteogenic
cells [52,64]. Moreover, mir145 and SOX2 are regulated by
EWS-FLI1, and TARBP2 dependent miRNA maturation appears
to be a major regulatory determinant of the cancer stem cells in
Ewing sarcoma [65,66]. Further hypothesis testing is required, as it
remains unknown if the CD99 distribution in such progenitor cells
is more variable and whether these cells are proliferative and so
relate in any way to our observations.
As we also demonstrate, biomarker classifiers based on arbitrary
cut-points of the imaged data could result in bias, a factor that
remains a significant impediment to current techniques [14,22].
These findings underscore the need for further unbiased
approaches to sample analysis in tumours, from quality control
to biomarker validation and clinical annotation. The high
dimensionality of collated imaging data, and in particular the
skewed distributions of biomarker image features, does require
novel analysis tools such as RSF [49]. Moreover, new strategies in
development that aim to reduce dimensionality, and so minimise
the risk of over fitting when using random forest, and ultimately
Figure 4. Random survival forest classifier error rates, distribution features and mortality. a. Error rates for nine RSF analyses trained with
the variable hunting algorithm, shown as box plots (median line, inter-quartile range box, minimum and maximum). SiBio refers to combined analysis
of signalling biomarkers Egr1, Foxo3a, pS6 with and without pMAPK*. Errors were lower for Ki-67 marker. See also Table 2. b. As each iteration of
variable hunting is independent, so the frequency of selection of each feature and its overall ranking can be shown following 100 re-samplings. c.
Selected features plotted (vertical lines) against the original distribution. Red and black lines indicate deceased and censored patients, with insert
showing magnified plots. d. Based on 100 iterations of variable hunting RSF, an overall mortality plot can be generated as a function of the RSF and
each feature. The top six (*) separate features are shown for the CD99 negative Ki-67 RSF, with the RSF integrating all ranked features` within one
classifier. Red crosses and black dots, deceased and censored patients, respectively.
doi:10.1371/journal.pone.0107105.g004
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the performance of these approaches, will likely redefine the
concept of sample size in biomedical applications [67]. As the
subsets of the genomic enriched classification of cancer further
sub-divide, rigid application of the ‘test-validation’ cohorts as
developed in biomarker guidelines such as REMARK are unlikely
to be helpful longer term, especially if data is directly linked to
genomic analysis [68,69]. In particular, the quality assurance at
the molecular level will be essential as a first analysis before any
prospect of useful cross-validation in independent cohorts can be
attempted, even if sample processing guidelines are followed, e.g.
BRISQ guidelines. Thus to maximise the informative and
predictive capabilities provided by unbiased machine learning
algorithms such as RF, the standardisation of protocols for
collecting and processing high quality material are still required
[25].
A further application of our methodology of single cell
segmentation and biomarker distribution could equally apply to
determining the response to agents and drugs. The relative
changes between multiple small core biopsies before and after
exposure to agents may identify cell populations resistant to target
inhibition. We are currently applying our methodology in a Ewing
sarcoma exploratory biomarker Phase II study (LINES trial,
EuroSarc) in patients with advanced disease. The drug tested in
this case is linsitinib, a dual IGF1R/IR-A kinase inhibitor.
In summary, we combined single cell imaging data from tissue
into a high dimensional feature distribution and a cross-validated
RSF to generate a pipeline for discovery of prognostic classifiers
(summarised in Figure 3). Importantly, such unbiased analysis can
lead to the generation of new hypotheses requiring testing, and in
particular relating to sub-populations of cells in a tumour that may
have a disproportionate contribution to clinical outcomes in
genetically characterised cancer sample cohorts.
Figure 5. Cross-validation of the full RSF algorithm. The imaging dataset was randomly partitioned into a training set (e.g. two-thirds of
patients = 79) and a testing set (one-third of patients = 39), with 50 repeats. Example results from 4 of the 50 cross-validation repeats for the CD99-
Ki67 RSF, encompassing the full range of error rates (0.22–0.53) shown in black). Patients in the test set were divided into two approximately equal
groups using the RSF predicted mortality (low, high) and survival curves plotted using the known survival data (solid lines), with a low error rate
corresponding to a difference in survival of the groups. In addition to predicting mortality the RSF could also predict an individual time dependent
survival curve for each patient (dashed lines). Plots are truncated at 2500 days, in some cases predicted survival times do not reach this far since they
are limited by the last event in the randomly selected training set. (see also Figure S12 in File S1).
doi:10.1371/journal.pone.0107105.g005
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Supporting Information
Table S1 Ewing sarcoma cell lines (EuroBoNeT).
(DOCX)
Table S2 Validation data of antibodies utilised.
(DOCX)
Table S3 Outcome data of Ewing sarcoma patients with
good and poor images.
(XLSX)
File S1 Figures S1–S13. Figure S1. Image segmentation
algorithm (OxBioPath- segmentation.v1). Figure S2. Heterogene-
ity of signalling responses quantified in Ewing cell lines. Figure S3.
Cumulative frequency plots of the Ewing sarcoma signalling
biomarkers. Figure S4. Heterogeneity of signalling pathway
activity in Ewing cell line cores. Figure S5. Image quality control
criteria. Figure S6. Patient survival comparison between imaged
and non-imaged cohort data. Figure S7. Automated quality
control classifier for DAPI images. Figure S8. Visualising the
distribution of cell features with principal components analysis.
Figure S9 Density plots of mean nuclear vs. mean cytoplasmic
CD99 and Ki67 in each segmented cell across all imaged patients
and cohorts. Figure S10, S11 and S12. Predicted relative mortality
and survival plots from random survival forest cross-validation.
Figure S13. Example of segmented tumour cell images showing
Ki67 positive CD99 negative (high nuclear: cytoplasmic ratio)
cells.
(PDF)
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